Jazz Pharmaceuticals plc

The momentum for this stock is not very good. Jazz Pharmaceuticals plc has good value characteristics. Jazz Pharmaceuticals plc is not very popular among insiders. Jazz Pharmaceuticals plc is a mediocre stock to choose.
Log in to see more information.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the ide...

News

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Headlands Technologies LLC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Headlands Technologies LLC

Zolmax Headlands Technologies LLC boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 96.3% in the 2nd quarter, according to its most recent disclosure with the Securities and...\n more…

Victory Capital Management Inc. Increases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Victory Capital Management Inc. Increases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Zolmax Victory Capital Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 42.7% in the second quarter, HoldingsChannel.com reports. The fund owned...\n more…

Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Needham & Company LLC
Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Needham & Company LLC

Zolmax Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)s stock had its "buy" rating reiterated by Needham Company LLC in a research note issued to investors on Tuesday, Benzinga reports...\n more…

Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Ticker Report Needham Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a report published on Tuesday, Benzinga reports. Needham Company LLC...\n more…

Cantor Fitzgerald Reiterates "Overweight" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Cantor Fitzgerald Reiterates "Overweight" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Ticker Report Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)s stock had its "overweight" rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga...\n more…

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Reaffirmed by Cantor Fitzgerald
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Reaffirmed by Cantor Fitzgerald

Zolmax Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)s stock had its "overweight" rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on...\n more…